Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Phoxilium® reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy

In English

Författare

Summary, in English

Background Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. Methods We retrospectively analysed 112 patients treated with CRRT at Skane University Hospital, Sweden. The control group was treated with Hemosol® B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium® (phosphate; n = 76) as dialysis fluid and Hemosol® B0 as replacement fluid. Results Hypophosphataemia (

Publiceringsår

2016-04-01

Språk

Engelska

Sidor

205-210

Publikation/Tidskrift/Serie

Clinical Kidney Journal

Volym

9

Issue

2

Dokumenttyp

Artikel i tidskrift

Förlag

Oxford University Press

Ämne

  • Urology and Nephrology

Nyckelord

  • critically ill patients
  • CRRT
  • hypophosphataemia
  • intensive care medicine

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 2048-8505